

Lead Pharma is entitled to receive royalty payments on global sales from any such products.

Further details of the financial terms have not been disclosed.

"Anti-ROR gamma t therapies represent a ground-breaking opportunity that we are eager and motivated to pursue through our collaboration with Lead Pharma," said Mr Christian Antoni, vice president and head of the immunology & inflammation franchise, R&D, Sanofi. "At Sanofi, we believe networked innovations - working collaboratively across science sectors - is the most effective way to bring meaningful new therapies to patients. To this end, Lead Pharma's innovative capabilities and productivity, exemplified by the ROR gamma t program, make them ideal partners for Sanofi in this area of drug discovery."